Business Description
Spexis AG
ISIN : CH0106213793
Share Class Description:
CHIX:SPEXz: Registered SharesCompare
Compare
Traded in other countries / regions
SPEX.Switzerland29Y.GermanySPEXz.UKPPHOF.USA IPO Date
2018-05-16Description
Spexis AG is a clinical-stage biopharmaceutical company. The company is engaged in the discovery and development of antibiotics and other specialty pharma products for severe or life-threatening diseases. The company's lead product, murepavadin, is in Phase III development against Pseudomonas aeruginosa - recognized as a critical priority 1 pathogen by World Health Organization. It has one operating segment focusing on the research and development and prospective commercialization of respiratory therapeutics addressing high unmet medical needs.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.05 | |||||
| Equity-to-Asset | 0.14 | |||||
| Debt-to-Equity | 3.64 | |||||
| Debt-to-EBITDA | -0.47 | |||||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -55.7 | |||||
| 3-Year EPS without NRI Growth Rate | -38.1 | |||||
| 3-Year FCF Growth Rate | -17.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 9-Day RSI | 40.05 | |||||
| 14-Day RSI | 42.38 | |||||
| 6-1 Month Momentum % | -22.7 | |||||
| 12-1 Month Momentum % | 14.96 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.38 | |||||
| Quick Ratio | 0.38 | |||||
| Cash Ratio | 0.05 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -73.9 | |||||
| Shareholder Yield % | -77.29 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -151.03 | |||||
| ROA % | -77.04 | |||||
| ROIC % | -79.3 | |||||
| ROC (Joel Greenblatt) % | -1603.23 | |||||
| ROCE % | -100.28 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.77 | |||||
| EV-to-EBIT | -0.66 | |||||
| EV-to-EBITDA | -0.69 | |||||
| EV-to-FCF | -1.81 | |||||
| Earnings Yield (Greenblatt) % | -152.3 | |||||
| FCF Yield % | -124.6 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Spexis AG Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil CHF) | |||
| EPS (TTM) (CHF) | 0 | ||
| Beta | -4.97 | ||
| Volatility % | 681.39 | ||
| 14-Day RSI | 42.38 | ||
| 14-Day ATR (CHF) | 0.000007 | ||
| 20-Day SMA (CHF) | 0.0538 | ||
| 12-1 Month Momentum % | 14.96 | ||
| 52-Week Range (CHF) | 0.0314 - 0.349 | ||
| Shares Outstanding (Mil) | 67.66 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Spexis AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Spexis AG Stock Events
| Event | Date | Price(CHF) | ||
|---|---|---|---|---|
| No Event Data | ||||
Spexis AG Frequently Asked Questions
What is Spexis AG(CHIX:SPEXz)'s stock price today?
The current price of CHIX:SPEXz is CHF0.05. The 52 week high of CHIX:SPEXz is CHF0.35 and 52 week low is CHF0.03.
When is next earnings date of Spexis AG(CHIX:SPEXz)?
The next earnings date of Spexis AG(CHIX:SPEXz) is .
Does Spexis AG(CHIX:SPEXz) pay dividends? If so, how much?
Spexis AG(CHIX:SPEXz) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers